Rubicon Research

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE506V01022
  • NSEID: RUBICON
  • BSEID: 544578
INR
1,837.90
-23.25 (-1.25%)
BSENSE

Sep 09, 11:47 AM

BSE+NSE Vol: 80.34 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

80.34 k (7.35%) Volume

Shareholding (Jun 2026)

FII

7.52%

Held by 39 FIIs

DII

9.43%

Held by 11 DIIs

Promoter

59.76%

Which are the latest news on Rubicon Research?

09-Sep-2026

Why is Rubicon Research Ltd falling/rising?

06-Sep-2026

As of 05-Sep, Rubicon Research Ltd's stock price is at 1,773.25, reflecting a slight decline of 0.05%. The recent drop in price is mainly due to decreased investor participation and concerns over valuation, despite the company's strong long-term growth and solid financial results.

As of 05-Sep, Rubicon Research Ltd's stock price is currently at 1,773.25, reflecting a slight decline of 0.9 points or 0.05%. The stock has been experiencing a downward trend, having fallen for the last two consecutive days, resulting in a total decrease of 3.35% during this period. This decline is occurring despite the stock's strong performance over the longer term, with a year-to-date increase of 161.62% compared to a 10.21% drop in the benchmark Sensex.<BR><BR>The recent price movement can be attributed to several factors. Notably, there has been a decrease in investor participation, as evidenced by a 12.58% drop in delivery volume compared to the five-day average. This reduced activity may indicate waning interest among investors, contributing to the stock's falling price. Additionally, while the stock is trading above its longer-term moving averages, it is currently below its five-day moving average, suggesting short-term weakness.<BR><BR>On the positive side, the company has demonstrated strong long-term fundamental strength, with a healthy net profit growth of 17.75% and positive results in the last two quarters. However, the stock's valuation appears expensive, with a price-to-book value of 22.7, which may deter some investors. Furthermore, institutional investors have reduced their stakes by 0.6% over the previous quarter, indicating a potential lack of confidence from larger investors, which can further impact the stock's performance.<BR><BR>In summary, while Rubicon Research Ltd has shown impressive long-term growth, the recent decline in stock price is primarily driven by falling investor participation and concerns over valuation, despite the company's solid financial results.

View full answer

What does Rubicon Research do?

01-Sep-2026

Rubicon Research Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 534 Cr and a net profit of 85 Cr for June 2026. Key metrics include a P/E ratio of 104.00 and a market cap of INR 30,246 Cr.

Overview:<BR>Rubicon Research Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Rubicon Research Limited was incorporated on May 6, 1999, originally as Rubicon Consultants Private Limited. The company later changed its name to Rubicon Research Private Limited on September 2, 2002. The latest quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 534 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 85 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 30,246 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 104.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.08% <BR>Debt Equity: -0.03 <BR>Return on Equity: 19.14% <BR>Price to Book: 23.13 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

View full answer

Who are the peers of the Rubicon Research?

01-Sep-2026

Rubicon Research's peers include Gland Pharma, Ajanta Pharma, Emcure Pharma, Sai Life, Wockhardt, Neuland Labs, Piramal Pharma, Acutaas Chemical, Pfizer, and Granules India. Notable performance includes Sai Life with a 76.70% 1-year return, while Pfizer has the lowest at -9.02%.

Peers: The peers of Rubicon Research are Gland Pharma, Ajanta Pharma, Emcure Pharma, Sai Life, Wockhardt, Neuland Labs., Piramal Pharma, Acutaas Chemical, Pfizer, Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma, Emcure Pharma, Neuland Labs., Acutaas Chemical, and Pfizer, while Good management risk is found at Gland Pharma, Sai Life, Wockhardt, and Granules India. Average management risk is noted at Piramal Pharma. In terms of Growth, Excellent growth is seen at Emcure Pharma, Sai Life, Neuland Labs., and Acutaas Chemical, while Below Average growth is reported for Gland Pharma, Ajanta Pharma, Wockhardt, Piramal Pharma, and Granules India. Good capital structure is present at Emcure Pharma, Sai Life, Neuland Labs., Acutaas Chemical, and Pfizer, while Excellent capital structure is noted at Gland Pharma, Ajanta Pharma, and Granules India, with Below Average capital structure at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sai Life at 76.70%, while the lowest is Pfizer at -9.02%. Rubicon Research's 1-year return is not available for comparison. Additionally, Pfizer and Wockhardt are the peers whose six-month return is negative.

View full answer

How big is Rubicon Research?

01-Sep-2026

As of 31st August, Rubicon Research Ltd has a market capitalization of 30,246.00 Cr, with recent net sales of 1,935.81 Cr and a net profit of 288.22 Cr.

As of 31st August, Rubicon Research Ltd has a market capitalization of 30,246.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Rubicon Research reported Net Sales of 1,935.81 Cr and a Net Profit of 288.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 1,288.82 Cr and Total Assets of 2,313.70 Cr.

View full answer

Should I buy, sell or hold Rubicon Research Ltd?

16-Aug-2026

Are Rubicon Research Ltd latest results good or bad?

14-Aug-2026

Rubicon Research Ltd's latest Q4 FY26 results are strong, with a net profit of ₹76.79 crores (up 111.83% year-on-year) and record revenue of ₹513.92 crores (up 43.49%). The operating margin also improved to 23.10%, indicating effective cost management and strong growth.

Rubicon Research Ltd's latest results for Q4 FY26 are quite impressive and can be considered good. The company reported a net profit of ₹76.79 crores, which represents a remarkable year-on-year growth of 111.83%. Additionally, revenue grew by 43.49% year-on-year, reaching ₹513.92 crores, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin also reached a record high of 23.10%, up from 20.24% in the same quarter last year, indicating effective cost management and operational efficiency. Furthermore, the Return on Capital Employed (ROCE) stands at a robust 28.31%, showcasing strong capital efficiency.<BR><BR>Overall, Rubicon's financial performance reflects a strong growth trajectory, with consistent improvements across key metrics, which has generated positive investor sentiment and significant stock performance.

View full answer

When is the next results date for Rubicon Research Ltd?

28-Jan-2026

The next results date for Rubicon Research Ltd is 03 February 2026.

The next results date for Rubicon Research Ltd is scheduled for 03 February 2026.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Low Debt Company with Strong Long Term Fundamental Strength

  • The company is Net-Debt Free
2

With a growth in Net Profit of 17.75%, the company declared Outstanding results in Jun 26

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 30,423 Cr (Small Cap)

stock-summary
P/E

107.00

stock-summary
Industry P/E

37

stock-summary
Dividend Yield

0.08%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

19.14%

stock-summary
Price to Book

23.90

Revenue and Profits:
Net Sales:
534 Cr
(Quarterly Results - Jun 2026)
Net Profit:
85 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.08%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.13%
0.12%
57.25%
6 Months
140.74%
0.20%
140.94%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 1.496583910700539 per share ex-dividend date: Aug-07-2026

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Rubicon Research Ltd Gains 4.67%: 6 Key Factors Driving the Surge

Announcements stock-summary

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

29-Aug-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

27-Aug-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for General Atlantic Singapore RR Pte Ltd

Shareholder Meeting / Postal Ballot-Scrutinizers Report

26-Aug-2026 | Source : BSE

Voting Results along with the Scrutinizers Report of the 27th Annual General Meeting of the Company held on Wednesday 26th August 2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
6.10
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.16
Tax Ratio
23.02%
Dividend Payout Ratio
0.23%
Pledged Shares
0
Institutional Holding
16.95%
ROCE (avg)
25.58%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
107
Industry P/E
37
Price to Book Value
23.90
EV to EBIT
86.69
EV to EBITDA
76.89
EV to Capital Employed
24.54
EV to Sales
17.54
PEG Ratio
NA
Dividend Yield
0.08%
ROCE (Latest)
28.31%
ROE (Latest)
19.14%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (7.23%)

FIIs

Held by 39 FIIs (7.52%)

Promoter with highest holding

General Atlantic Singapore Rr Pte Ltd (35.83%)

Highest Public shareholder

Shivanand Shankar Mankekar Huf (13.52%)

Individual Investors Holdings

3.46%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 9.71% vs 29.22% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 17.75% vs 88.33% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "427.73",
          "val2": "389.88",
          "chgp": "9.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "124.83",
          "val2": "106.17",
          "chgp": "17.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.01",
          "val2": "5.40",
          "chgp": "11.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "82.45",
          "val2": "70.02",
          "chgp": "17.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "29.18%",
          "val2": "27.23%",
          "chgp": "1.95%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "614.49",
          "val2": "528.16",
          "chgp": "16.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142.24",
          "val2": "144.68",
          "chgp": "-1.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.06",
          "val2": "16.26",
          "chgp": "11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "80.96",
          "val2": "89.04",
          "chgp": "-9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.15%",
          "val2": "27.39%",
          "chgp": "-4.24%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "916.20",
          "val2": "773.03",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "204.48",
          "val2": "208.58",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "25.57",
          "val2": "23.51",
          "chgp": "8.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "118.14",
          "val2": "127.27",
          "chgp": "-7.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.32%",
          "val2": "26.98%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,753.96",
          "val2": "1,284.27",
          "chgp": "36.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "400.24",
          "val2": "264.26",
          "chgp": "51.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "42.17",
          "val2": "36.78",
          "chgp": "14.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "246.74",
          "val2": "134.36",
          "chgp": "83.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.82%",
          "val2": "20.58%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
427.73
389.88
9.71%
Operating Profit (PBDIT) excl Other Income
124.83
106.17
17.58%
Interest
6.01
5.40
11.30%
Exceptional Items
0.00
0.00
Standalone Net Profit
82.45
70.02
17.75%
Operating Profit Margin (Excl OI)
29.18%
27.23%
1.95%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 9.71% vs 29.22% in Mar 2026

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 17.75% vs 88.33% in Mar 2026

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
614.49
528.16
16.35%
Operating Profit (PBDIT) excl Other Income
142.24
144.68
-1.69%
Interest
18.06
16.26
11.07%
Exceptional Items
0.00
0.00
Standalone Net Profit
80.96
89.04
-9.07%
Operating Profit Margin (Excl OI)
23.15%
27.39%
-4.24%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
916.20
773.03
18.52%
Operating Profit (PBDIT) excl Other Income
204.48
208.58
-1.97%
Interest
25.57
23.51
8.76%
Exceptional Items
0.00
0.00
Standalone Net Profit
118.14
127.27
-7.17%
Operating Profit Margin (Excl OI)
22.32%
26.98%
-4.66%
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,753.96
1,284.27
36.57%
Operating Profit (PBDIT) excl Other Income
400.24
264.26
51.46%
Interest
42.17
36.78
14.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
246.74
134.36
83.64%
Operating Profit Margin (Excl OI)
22.82%
20.58%
2.24%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025

stock-summaryCompany CV
About Rubicon Research Ltd stock-summary
stock-summary
Rubicon Research Ltd
Small Cap
Pharmaceuticals & Biotechnology
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
Company Coordinates stock-summary
Icon
No Company Details Available